TGTX BRIUMVI on track for $1B run rate amid pipeline expansion
BRIUMVI is on track for a $1 billion run rate, supported by commercial expansion and a clinical pipeline targeting MS and other indications. SubQ formulation is expected to drive future growth, with patent protection extending to 2042.
BRIUMVI is on track for a $1 billion run rate, supported by commercial expansion and a clinical pipeline focused on MS and other indications. The SubQ formulation is expected to drive further growth, while patent protection extends to 2042. Nationwide marketing and new indications are also key.